0000000001026594

AUTHOR

Jaume Barallat

showing 13 related works from this author

Clinical Role of CA125 in Worsening Heart Failure

2020

Abstract Objectives The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF). Background CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification. Methods In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by usin…

medicine.medical_specialtyFramingham Risk Scoreendocrine system diseasesbusiness.industrymedicine.drug_class030204 cardiovascular system & hematologymedicine.diseaseTailored treatmentfemale genital diseases and pregnancy complications03 medical and health sciences0302 clinical medicineIncreased riskHeart failureInternal medicineCohortmedicineNatriuretic peptideBiomarker (medicine)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessJACC: Heart Failure
researchProduct

Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure

2015

Abstract Objectives This study sought to examine the prognostic value of the soluble form of neprilysin (sNEP) in acute heart failure (AHF) and sNEP kinetics during hospital admission. Background sNEP was recently identified in chronic heart failure (HF) and was associated with cardiovascular outcomes. Methods A total of 350 patients (53% women, mean 72.6 ± 10.7 years of age) were included in the study. Primary endpoints were composites of cardiovascular death or HF hospitalizations at short-term (2 months) and long-term (mean: 1.8 ± 1.2 years) follow-up. sNEP was measured using an ad hoc–modified enzyme-linked immunosorbent assay, and its prognostic value was assessed using Cox regression …

medicine.medical_specialtyEjection fractionProportional hazards modelbusiness.industryHazard ratioProhormonemedicine.diseaseBrain natriuretic peptideGastroenterologyConfidence intervalHeart failureInternal medicinemedicineCardiology and Cardiovascular MedicineIntensive care medicinebusinessNeprilysinmedicine.drugJACC: Heart Failure
researchProduct

A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

2019

Sudden cardiac death (SCD) is one of the main modes of death in heart failure (HF) patients and its prediction remains a real challenge. Our aim was to assess the incidence of SCD at 5 years HF contemporary managed outpatients, and to find a simple prediction model for SCD.SCD was considered any unexpected death, witnessed or not, occurring in a previously stable patient with no evidence of worsening HF or any other cause of death. A competing risk strategy was adopted using the Fine-Gray method of Cox regressions analyses that considered other causes of death as the competing event.The derivation cohort included 744 consecutive outpatients (72% men, age 67.9 ± 12.2 years, left ventricular …

Malemedicine.medical_specialty030204 cardiovascular system & hematologySudden deathSudden cardiac deathCohort Studies03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineAmbulatory CaremedicineHumanscardiovascular diseases030212 general & internal medicineAgedCause of deathAged 80 and overHeart FailureUnivariate analysisEjection fractionTroponin Tbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseDeath Sudden CardiacHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients.

2018

Background Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Methods Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mo…

Malemedicine.medical_specialtyFrail ElderlyPopulationComorbidity030204 cardiovascular system & hematologylcsh:GeriatricsPatient Readmission03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathNatriuretic Peptide BrainClinical endpointmedicineHumans030212 general & internal medicineProspective StudieseducationProspective cohort studyAgedAged 80 and overHeart Failureeducation.field_of_studyPredictive markerSurrogate endpointbusiness.industryHazard ratioMembrane Proteinsmedicine.diseasePrognosisComorbidityPeptide Fragmentslcsh:RC952-954.6CA-125 AntigenBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersResearch ArticleFollow-Up Studies
researchProduct

Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.

2018

Abstract Background Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. Methods 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12.5%), and 135 with HFpEF (12.5%). We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), soluble suppression of tumorigenicity (ST2), galectin-…

Malemedicine.medical_specialtymedicine.drug_classGalectin 3030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin TInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overHeart FailureEjection fractionbiologyTroponin Tbusiness.industryHazard ratioStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisPeptide FragmentsDeathHeart failureChronic Diseasebiology.proteinCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational journal of cardiology
researchProduct

Serum neprilysin and recurrent hospitalizations after acute heart failure

2016

Malemedicine.medical_specialty030204 cardiovascular system & hematologyPatient ReadmissionCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumans030212 general & internal medicineProspective StudiesNeprilysinAgedAged 80 and overHeart Failurebusiness.industryMiddle Agedmedicine.diseaseHospitalizationEchocardiographyHeart failureCardiologyFemaleNeprilysinCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

2017

Background Our aim was to evaluate the association between the soluble form of neprilysin ( sNEP ) levels and long‐term all‐cause, cardiovascular, and acute heart failure ( AHF ) recurrent admissions in an ambulatory cohort of patients with heart failure. sNEP has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. Methods and Results We measured sNEP levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all‐cause, cardiovascular, and AHF hospitalizations during…

Malemedicine.medical_specialtyTime Factorsmedicine.drug_class030204 cardiovascular system & hematologyPatient Readmissionneprilysin03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInterquartile rangeCause of DeathInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineAgedOriginal ResearchAged 80 and overHeart Failurereadmissionbusiness.industryIncidenceMiddle AgedPrognosismedicine.diseasePeptide FragmentsConfidence intervalUp-RegulationQuartileSpainHeart failureCohortAmbulatoryCardiologyBiomarker (medicine)FemaleNeprilysinCardiology and Cardiovascular MedicinebusinessReadmissionBiomarkers
researchProduct

Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 3: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S3. Cox regression analyses for 1-year HF-related hospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 2: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S2. Cox regression analyses for 30-day rehospitalization. A competing risk strategy using the Gray method was adopted, considering death as the competing risk in both univariate and multivariate Cox regression analyses. (DOCX 27 kb)

researchProduct

Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25 kb)

researchProduct

Additional file 1: of Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

2018

Table S1. Correlations between studied biomarkers. Correlation between the different studied biomarkers was performed using Pearson correlation test of log-transformed values of each biomarker. (DOCX 25 kb)

researchProduct